Spots Global Cancer Trial Database for Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer
Official Title: A Phase II Investigation of Oral Vinorelbine in Combination With Trastuzumab for 1st and 2nd Line Treatment of Women With Metastatic HER2 Positive Breast Cancer
Study ID: NCT01242449
Conditions
Study Description
Brief Summary: This phase II study will investigate oral vinorelbine 90 mg/m2 on days 1 + 8 at 3 weeks intervals in combination with trastuzumab as 1st and 2nd line treatment of women with metastatic HER2 positive breast cancer. Oral vinorelbine has shown the same overall response rate as i.v. vinorelbine in metastatic breast cancer, and capsules are generally better tolerated.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Dept. of Oncology, Aalborg Sygehus, Aalborg, , Denmark
Dept. of Oncology, Esbjerg Hospital, Esbjerg, , Denmark
Department of Oncology, Vejle Hospital, Vejle, , Denmark
Contact Details
Name: Troels Bechmann, MD
Affiliation: Department of Oncology, Vejle Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Erik H Jakobsen, MD
Affiliation: Department of Oncology, Vejle Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
